GHRP-2: What the Research Shows About This Second-Generation GH Secretagogue

What it is

Ghrelin is the hormone your stomach makes when it is empty. It makes you hungry, and it also tells the pituitary to release growth hormone. In the 1980s and 90s, before anyone had found ghrelin itself, Cyril Bowers and colleagues built small synthetic peptides that triggered growth hormone release through what turned out to be ghrelin’s receptor. GHRP-6 was the first. GHRP-2, six amino acids long, was the improved second version: more growth hormone per dose, a little less hunger.

Japan later approved it under the name pralmorelin, as a diagnostic: give one dose, measure the growth hormone response, and you can tell whether someone’s pituitary works. That is the only approval it has anywhere. Nobody has run a trial of GHRP-2 as a treatment.

What it is studied for

Growth hormone release, in single-dose human studies. Diagnosing growth hormone deficiency. How it combines with GHRH-type peptides. Its effect on appetite. Everything about muscle, fat loss, or recovery comes from what growth hormone does in general and from user reports, not from a GHRP-2 trial.

What the evidence actually shows

In humans

Bowers’ group showed that GHRP-2 produces a strong, dose-dependent growth hormone pulse in healthy adults and in people with growth hormone deficiency, larger than GHRP-6 at the same dose (Bowers et al., 1994). Japanese studies confirmed the response was reliable enough to separate people with deficient pituitaries from people with normal ones, which is what got it approved as a test (Kojima et al., 2016).

Given together with a GHRH-type peptide, the growth hormone pulse is far bigger than either alone, because the two act on different receptors that reinforce each other. This is the mechanism behind stacking GHRP-2 with CJC-1295 or sermorelin.

The same studies recorded the downsides. GHRP-2 raises cortisol and prolactin for an hour or two after a dose, less than GHRP-6 but more than ipamorelin, and it increases hunger, because ghrelin’s receptor is the hunger receptor (Arvat et al., 1997).

That is the human record: it does what it is designed to do, measured over hours. Nobody has measured what weeks or months of it do to a person’s body.

From user reports

People describe a clear appetite surge after each dose, better sleep with a bedtime dose, water retention, and gradual body-composition changes over an 8-to-12-week cycle, almost always while also stacking a GHRH peptide and training. None of it has been measured in a study.

How it works

GHRP-2 binds the ghrelin receptor on pituitary cells and in the hypothalamus. It triggers growth hormone release directly, boosts the brain’s own GHRH signal, and partly lifts the somatostatin brake that normally holds growth hormone back. That last part is why it pairs well with GHRH-type peptides, which cannot get past the brake on their own.

The receptor it hits is not selective. Activating it also nudges the stress axis (cortisol), prolactin, and hunger. Ipamorelin was later designed to hit growth hormone without the other three.

How it is used in studies

The diagnostic test uses a single intravenous dose of 100 micrograms. Users inject 100 to 300 micrograms under the skin, two or three times a day on an empty stomach, often with an equal dose of a GHRH peptide in the same syringe, for 8 to 12 weeks. Those numbers are user practice. See the stacks guide and the storage guide.

Side effects and unknowns

Documented in the human studies: hunger, brief cortisol and prolactin rises, flushing, tiredness. Reported by users: water retention, tingling in the hands, and headaches, all standard growth hormone effects.

The unknowns are the same as for every growth hormone peptide. Growth hormone opposes insulin, so blood sugar can rise. IGF-1 goes up, and long-term high IGF-1 has a theoretical cancer link. The receptor can desensitize with continuous stimulation, which is one argument for spacing doses. Repeated cortisol bumps several times a day, every day, have never been studied. See the safety guide.

How it compares

• GHRP-6: the original; less growth hormone per dose, more hunger, more cortisol.
• Ipamorelin: the selective one. Similar growth hormone release with almost no cortisol, prolactin, or hunger. Most people who once used GHRP-2 now use this.
• Hexarelin: the strongest single pulse of the group, with the fastest desensitization.
• MK-677: a pill that hits the same receptor and stays active all day; more human data, more hunger and blood-sugar effect.
• CJC-1295 and sermorelin: GHRH-type, the other half of the stack. See the muscle growth guide.

Legal status

Approved in Japan as a diagnostic agent only. Not FDA approved for anything; sold as a research chemical in the United States. WADA bans it in and out of competition, and anti-doping labs can detect it.

Bottom line

GHRP-2 reliably makes the pituitary release growth hormone, which is proven, and it does it with more hunger and cortisol than ipamorelin, which is why it fell out of favor. What a growth hormone pulse three times a day does to your muscle, fat, or health over months has not been studied for this or any peptide in its class.

References

1. Bowers CY, et al. (1994). Growth hormone-releasing peptide (GHRP). Cell Mol Life Sci. PubMed
2. Arvat E, et al. (1997). Endocrine activities of growth hormone secretagogues. J Clin Endocrinol Metab. PubMed
3. Kojima M, et al. (2016). The role of the growth hormone secretagogue receptor in the diagnosis of growth hormone deficiency. Endocr J. PubMed

See also

• Peptide
  GHRP-6: What the Research Shows About This Growth Hormone Releasing Peptide

  GHRP-6 is the six-amino-acid peptide that led to the discovery of the ghrelin receptor. It reliably releases growth hormone in people and makes them very hungry. No trial has tested it for muscle or recovery.

• Peptide
  CJC-1295: What the Evidence Says About This GHRH Analog

  CJC-1295 is a longer-lasting version of GHRH, the signal that tells the pituitary to release growth hormone. The DAC form raised GH and IGF-1 for days in one small trial; the no-DAC form (Mod GRF 1-29) has no human trial of its own.

• Peptide
  Hexarelin: What the Research Shows About This Potent GH Secretagogue

  Hexarelin is the most potent growth hormone releasing peptide in human studies, roughly two to three times GHRP-6, with a receptor of its own in heart muscle. Its catch is desensitization: the effect fades within weeks of daily use.